Dark Horse Consulting Group Inc.
Kimberly Benton has extensive work experience in the regulatory field. Kimberly currently holds the position of Master Principal and Head of Regulatory at Dark Horse Consulting Group Inc. since January 2023. Prior to that, they worked at FDA CBER where they held various roles, including Associate Director for Regulatory Management, Deputy Director of the Division of Cellular and Gene Therapies, and Branch Chief of the Cellular Therapies Branch. Kimberly also worked as a Microbiologist/Chemistry, Manufacturing, and Controls Reviewer during their time at FDA CBER. Kimberly'stenure at FDA CBER spanned from June 2000 to December 2022.
Kimberly Benton attended the University of Alabama at Birmingham from 1990 to 1997. The degree attained, if any, and the field of study are not specified.
This person is not in any offices
Dark Horse Consulting Group Inc.
AT DARK HORSE CONSULTING, we work to accelerate cell and gene therapies through our unmatched expertise. Our consulting team has extensive CGT industry experience with knowledge spanning manufacturing, process development, comparability, analytical dev, quant modeling, quality systems, regulatory support, preclinical dev, device dev, program management, facility design and enginnering, market research, and due diligence and business strategy. Many of our consultants also bring experience from adjacent, more mature, sectors, including traditional biologics, small molecules, medical devices, and management consulting. Client requests range from scientific expertise to tactical needs to strategic considerations to business development. We understand the unique challenges faced by Cell and Gene Therapy developers like none other. We apply best practices from across this and other industries to address the needs of our clients, who range from biopharmaceutical companies to tools & tech providers to investment firms.